

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>EISENBERG GLENN A</u>  (Last) (First) (Middle) <u>531 SOUTH SPRING STREET</u>  (Street) <u>BURLINGTON NC 27215</u>  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>LABORATORY CORP OF AMERICA HOLDINGS [ LH ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Chief Financial Officer, EVP</u>
	3. Date of Earliest Transaction (Month/Day/Year) <u>11/01/2022</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	11/01/2022		M		12,032	A	(1)	39,190	D	
Common Stock	11/01/2022		F <sup>(2)</sup>		5,348	D	\$222.56	33,842	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Performance Share Unit <sup>(3)</sup>	(4)	11/01/2022		A		9,170		(5)	05/10/2024 <sup>(5)</sup>	Common Stock	9,170	\$0	9,170	D	
Restricted Stock Unit	(1)	11/01/2022		A		9,170		(6)	(6)	Common Stock	9,170	\$0	25,876	D	
Restricted Stock Unit	(1)	11/01/2022		M			12,032	(7)	(7)	Common Stock	12,032	\$0	13,844 <sup>(8)</sup>	D	

**Explanation of Responses:**

- Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.
- Stock withholding to satisfy tax withholding obligations.
- Performance Share Unit granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan.
- Each Performance Share Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.
- The Performance Share Units vest in full upon the filing of the Company's Quarterly Report on Form 10-Q for the first quarter of 2024, subject to both continued service and a performance condition related to the Issuer's contemplated spin-off transaction.
- The Restricted Stock Units vest in full on April 15, 2024.
- The Restricted Stock Units that have vested were part of a grant that vested in three installments as follows: 30% of the Restricted Stock Units vested on November 1, 2020; 30% of the Restricted Stock Units vested on November 1, 2021; and 40% of the Restricted Stock Units vested on November 1, 2022, with the third installment subject to a relative total shareholder return ("TSR") modifier that could have adjusted the third installment of the Restricted Stock Units upward or downward 25% based on our three-year cumulative relative TSR but ultimately did not result in an adjustment.
- This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

/s/ Sandra D. van der Vaart,  
Attorney-in-Fact for Glenn A. Eisenberg      11/03/2022

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.